However, a 26-year-old woman diagnosed with treatment-refractory HLH caused by EBV and acute hepatitis C virus infection achieved completely recovery after the use of ruxolitinib.[19] In a series of children cases reported in China, the authors reported poor response to ruxolitinib alone in EBV-HLH when compared with other causes of HLH.[20] The authors suggested that ruxolitinib might not be able to eradicate EBV because EBV does not solely rely on JAK-STAT pathway to cause HLH. The gene discussed is SOAT1; the disease is hemophagocytic syndrome.